Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

04.02.2025 15:07:08

EQS-News: GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

EQS-News: GeoVax, Inc. / Key word(s): Financial
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

04.02.2025 / 15:07 CET/CEST
The issuer is solely responsible for the content of this announcement.


ATLANTA, GA - February 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present GeoVax’s 2025 strategic vision and milestones at the 2025 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 10-12, 2025.

Presentation Details:
Presenter: David Dodd, Chairman & CEO
Date/Time: February 10, 2025, 10:15 am ET
Location: New York Marriott Marquis, Plymouth Room
Registration: BIO CEO & Investor Conference

GeoVax senior management will also conduct one-on-one meetings throughout the conference. For more information or to schedule a meeting, please visit the conference page here or contact GeoVax Investor Relations.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin combined with an immune checkpoint inhibitor is planned to initiate in mid-2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Company Contact: Investor Relations Contact: Media Contact:
info@geovax.com austin.murtagh@precisionaq.com sr@roberts-communications.com 
678-384-7220 212-698-8696 202-779-0929

View the original release on www.newmediawire.com


News Source: GeoVax, Inc.


04.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: GeoVax, Inc.
United States
ISIN: US3736782000
EQS News ID: 2081021

 
End of News EQS News Service

2081021  04.02.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2081021&application_name=news&site_id=finanzen_net~~~069d1026-6a45-454f-953c-2a2c4451f1d6
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

DeepSeek: KI-Branche unter Druck – Wall Street Live mit Tim Schäfer
🚨🚨🚨 China schlägt Nvidia: Billig-KI schockt die Tech-Welt und lässt Aktien taumeln! 🤔

In unserer heutigen Folge spricht Tim Schäfer im Interview mit David Kunz, COO der BX Swiss AG über das kürzlich erschienene DeepSeek und welche Auswirkungen die künstliche Intelligenz diese Woche auf die Märkte hatte. Welche Hintergründe hat DeepSeek, wie sieht die langfristige Entwicklung in der Branche aus und warum ist Europa praktisch von der Entwicklung abgehängt?

In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

DeepSeek: KI-Branche unter Druck – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’949.57 19.92 2MSSMU
Short 13’234.22 13.68 SS0MDU
Short 13’736.81 8.83 UBSP6U
SMI-Kurs: 12’475.49 04.02.2025 17:31:15
Long 11’940.00 19.97
Long 11’680.00 13.79
Long 11’182.60 8.99 SSRM0U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten